Dengue vaccines are shots designed to help protect you from getting dengue fever. There are different kinds of vaccines being tested or used, like shots that use weakened virus or parts of the virus.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Dengue vaccines are meant to prevent dengue, a mosquito-borne viral infection common in tropical and subtropical regions. Dengue is caused by four related viruses, so a person can be infected more than once, and a second infection with a different type carries a higher risk of severe dengue, which can cause shock and internal bleeding. The only dengue vaccine licensed in the United States is Dengvaxia, made by Sanofi Pasteur. It was approved for children and teens who had a laboratory-confirmed dengue infection in the past and lived in places where dengue is common, including US areas where it spreads locally. US health officials recommended it for ages 9 to 16. Sanofi discontinued it because of low demand, and the Centers for Disease Control and Prevention (CDC) reports that it is no longer available in the United States. Other dengue vaccines are used elsewhere. Qdenga, made by Takeda, is authorized in Europe and more than 40 other countries, and the World Health Organization recommends it for children aged 6 to 16 in areas with heavy dengue transmission. Takeda withdrew its US application in 2023, so Qdenga is not available or recommended in the US. A single-dose vaccine developed by the US National Institutes of Health was approved in Brazil in late 2025, but Brazil paused its use in June 2026 while it reviews reports of side effects. For now, people in the US, including travelers, rely on preventing mosquito bites.
Dengue vaccines contain live dengue viruses that have been weakened so they do not cause the disease. The immune system responds to them by making antibodies and other defenses against all four dengue types, so it can react faster if a real infection comes later. The exact way this protection works is not fully understood. Protection is not equal across people or across the four virus types. The vaccines studied so far work better in people who have already had dengue. With Dengvaxia, the immune response in someone never infected can resemble a first infection, so a later real infection behaves more like a second one, which is the setting where severe dengue is more likely. That is why Dengvaxia was restricted to people with proof of a past infection.
Dengvaxia was given as three injections under the skin, six months apart, so the full series took a year. Before the first dose, a clinician had to confirm a past dengue infection, either from a medical record of a laboratory-confirmed case or with a blood test for dengue antibodies. No test cleared by the US Food and Drug Administration (FDA) exists for this purpose, and available tests can give false positive results because antibodies to related mosquito-borne viruses can cross-react. Qdenga, where it is used, is given as two injections under the skin of the upper arm, three months apart. Its European authorization does not require a past infection.
In Dengvaxia's trials in 9- to 16-year-olds, the most common reactions within two weeks of a dose were headache, pain at the injection site, a general sense of feeling unwell, weakness and muscle aches. These are usually short-lived. Qdenga's common side effects are similar, including injection site pain and redness. Some people feel faint around the time of an injection, so sitting or lying down for a short while afterward helps prevent falls. As with any vaccine, a severe allergic reaction is possible but rare, and vaccination sites are prepared to treat it. The most important serious risk is severe dengue after a later real infection, described under Interactions & Warnings. Anyone who has been vaccinated and develops fever with body aches, pain behind the eyes or a rash, especially after time in a dengue area, should see a clinician and mention the vaccine and recent travel. Severe dengue warning signs often appear a day or two after the fever eases: severe belly pain, vomiting at least three times in a day, bleeding from the nose or gums, blood in vomit or stool, or unusual sleepiness, restlessness or irritability. These need immediate medical care.
Dengvaxia should not be given to anyone who has never had dengue or whose history is unknown. In those people, vaccination is linked to a higher risk of severe dengue, including hospitalization, if they are infected later. It is also not approved for children under 6, who had a higher risk of severe dengue after vaccination whether or not they had been infected before. Its safety and effectiveness have not been established for travelers from places without dengue. Because dengue vaccines contain live virus, they are not given to people with severely weakened immune systems, whether from an illness such as advanced HIV (human immunodeficiency virus) or from treatments such as chemotherapy or high-dose steroids. These treatments can also weaken the response to the vaccine. Anyone who had a severe allergic reaction to an earlier dose should not receive another. Dengvaxia can cause a false negative result on a tuberculosis skin test for about a month, so the test is done before vaccination or at least a month after. Information on dengue vaccination during pregnancy is limited; Qdenga is not used during pregnancy or breastfeeding in Europe.
In children who had dengue before, Dengvaxia cut confirmed cases of symptomatic dengue by about 80% in the year after the third dose. In Qdenga's main study of about 20,000 children, confirmed dengue illness fell by about 80% and dengue hospitalizations by about 90%. Neither vaccine protects everyone, and protection is uneven across the four dengue types, so vaccinated people still need to avoid mosquito bites with repellent, covering clothing and screened windows. In the US, there is currently no dengue vaccine to receive. People who started the Dengvaxia series and could not finish it, or who live in or travel to dengue areas, can ask a clinician what protection makes sense now. Vaccine options may change as other vaccines continue through trials and regulatory review.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Dengue Vaccines, what you've noticed, or ask the community a question.